XML 82 R65.htm IDEA: XBRL DOCUMENT v3.24.0.1
Identifiable Intangible Assets - Additional Information (Detail)
$ in Millions
12 Months Ended
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Finite-Lived Intangible Assets [Line Items]      
Amortization of intangible assets useful life 9 years    
Amortization of intangible assets $ 616 $ 732 $ 802
2024 503    
2025 460    
2026 462    
2027 451    
2028 398    
Impairment of intangible assets excluding goodwill $ 350 355 424
Inventory write down   4,200  
Change In Tevas Commercial Plans Regarding Certain Program [Member]      
Finite-Lived Intangible Assets [Line Items]      
Inventory write down   $ 108  
Minimum [Member] | Measurement input, discount rate [Member]      
Finite-Lived Intangible Assets [Line Items]      
Business combination, contingent consideration, liability, measurement input 8.5    
Maximum [Member] | Measurement input, discount rate [Member]      
Finite-Lived Intangible Assets [Line Items]      
Business combination, contingent consideration, liability, measurement input 11    
In Process Research and Development [Member] | Minimum [Member]      
Finite-Lived Intangible Assets [Line Items]      
Business combination, contingent consideration, liability, measurement input   8.5  
In Process Research and Development [Member] | Minimum [Member] | Measurement input, discount rate [Member]      
Finite-Lived Intangible Assets [Line Items]      
Business combination, contingent consideration, liability, measurement input   20  
In Process Research and Development [Member] | Maximum [Member]      
Finite-Lived Intangible Assets [Line Items]      
Business combination, contingent consideration, liability, measurement input   10  
In Process Research and Development [Member] | Maximum [Member] | Measurement input, discount rate [Member]      
Finite-Lived Intangible Assets [Line Items]      
Business combination, contingent consideration, liability, measurement input   90  
In Process Research and Development [Member] | Generic Pipeline Products [Member]      
Finite-Lived Intangible Assets [Line Items]      
Impairment of intangible assets excluding goodwill     127
In Process Research and Development [Member] | Generic Pipeline Products [Member] | Development Progress And Changes In Other Key Valuation Assumptions [Member]      
Finite-Lived Intangible Assets [Line Items]      
Impairment of intangible assets excluding goodwill $ 90 $ 45  
Identifiable product rights [Member]      
Finite-Lived Intangible Assets [Line Items]      
Impairment of intangible assets excluding goodwill 260 310  
Identifiable product rights [Member] | Regulatory Price And Volume Of Products [Member]      
Finite-Lived Intangible Assets [Line Items]      
Impairment of intangible assets excluding goodwill 148    
Identifiable product rights [Member] | Updated Market Assumptions [Member]      
Finite-Lived Intangible Assets [Line Items]      
Impairment of intangible assets excluding goodwill   256  
Identifiable product rights [Member] | Change In Tevas Commercial Plans Regarding Certain Program [Member]      
Finite-Lived Intangible Assets [Line Items]      
Impairment of intangible assets excluding goodwill   $ 54  
Identifiable product rights [Member] | Lenalidomide Product [Member]      
Finite-Lived Intangible Assets [Line Items]      
Impairment of intangible assets excluding goodwill     267
Actavis [Member] | Identifiable product rights [Member]      
Finite-Lived Intangible Assets [Line Items]      
Impairment of intangible assets excluding goodwill     297
Japan [Member] | Identifiable product rights [Member] | Updated Market Assumptions [Member]      
Finite-Lived Intangible Assets [Line Items]      
Impairment of intangible assets excluding goodwill $ 112    
United States [Member] | Actavis [Member] | Identifiable product rights [Member]      
Finite-Lived Intangible Assets [Line Items]      
Impairment of intangible assets excluding goodwill     $ 30